Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jade Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jade Biosciences's regulatory disclosures and financial reporting.
Form 144 Notice of Proposed Sale filed by Jade Biosciences indicates a planned sale of 28,977 shares with an aggregate market value of $303,678.96 through Merrill Lynch on the Nasdaq exchange, scheduled for June 25, 2025.
The securities were originally acquired through a Private Placement from the issuer on June 4, 2021, purchased with cash. The total outstanding shares are 28,985,019.
Recent Trading Activity:
- Atlas Ventures Fund XII LP and Atlas Ventures Associates XII LP have conducted multiple sales in the past 3 months
- Most recent transactions occurred June 24-25, 2025, with Atlas Ventures Fund XII LP selling 16,132 shares ($167,776.03)
- Total combined recent sales by Atlas entities amount to approximately 22,429 shares
Form 144 Notice of Proposed Sale filed by Jade Biosciences (NASDAQ: JBIO) on June 28, 2025, detailing planned insider stock sales. The filing indicates a proposed sale of 235 shares with an aggregate market value of $2,462.80 through Merrill Lynch, representing a small portion of the total 28,985,019 shares outstanding.
Key transaction details:
- Shares were originally acquired through Private Placement on June 4, 2021
- Planned sale date: June 25, 2025
- Current market price implies approximately $10.48 per share
Recent insider selling activity by Atlas Ventures entities in the past 3 months totals 51,171 shares for aggregate proceeds of $537,316.10, including significant sales by Atlas Ventures Fund XII LP (50,992 shares) and smaller transactions by Atlas Venture Associates XII, LP (179 shares). This Form 144 filing suggests continued insider selling pressure while affirming no knowledge of undisclosed material adverse information.
Jade Biosciences (NASDAQ: JBIO) has filed a Form 144 notice indicating a proposed sale of 16,132 shares with an aggregate market value of $159,222.84. The securities are to be sold through Merrill Lynch, with the planned transaction date of June 24, 2025.
The shares were originally acquired through a Private Placement from the issuer on June 4, 2021, with cash payment. The total outstanding shares of the company are 28,985,019.
Recent insider trading activity includes:
- Atlas Ventures Fund XII LP sold 5,883 shares for $64,061.73 on May 6, 2025
- Atlas Ventures Associates XII LP made two sales: 48 shares for $498.84 on May 6, 2025, and 131 shares for $1,292.97 on June 24, 2025
This Form 144 filing represents the declaration of intention to sell restricted securities, as required by SEC Rule 144 under the Securities Act of 1933.
Form 144 Notice of Proposed Sale filed by Atlas Ventures for Jade Biosciences (NASDAQ: JBIO) indicates planned insider stock sales. The filing details a proposed sale of 131 shares at an aggregate market value of $1,292.97 through Merrill Lynch, with execution planned for June 24, 2025.
Key transaction details:
- Shares were originally acquired through private placement on June 4, 2021
- Current total shares outstanding: 28,985,019
- Recent related sales in past 3 months:
- Atlas Ventures Fund XII LP: 5,883 shares ($64,061.73) on May 6, 2025
- Atlas Venture Associates XII LP: 48 shares ($498.84) on May 6, 2025
- Atlas Ventures Fund XII LP: 16,132 shares ($159,222.84) on June 24, 2025
The filing indicates no knowledge of material adverse information regarding Jade Biosciences' operations that hasn't been publicly disclosed.
Deep Track Capital and affiliates have disclosed an 8.64% ownership stake in Jade Biosciences, representing 2,784,648 shares of common stock. The Schedule 13G filing reveals three reporting entities: Deep Track Capital LP, Deep Track Biotechnology Master Fund Ltd, and David Kroin.
Key details of the ownership structure:
- All three entities share voting and dispositive power over 2,784,648 shares
- None of the reporting persons have sole voting or dispositive power
- Ownership percentage is calculated based on 32,235,926 shares outstanding as of April 28, 2025
- David Kroin serves as both Managing Member of Deep Track Capital's General Partner and Director of Deep Track Biotechnology Master Fund
The filing certifies that the securities were not acquired to influence control of Jade Biosciences. The reporting persons have entered into a joint filing agreement, with each party responsible for their own information accuracy while sharing filing obligations.
FAQ
What is the current stock price of Jade Biosciences (JBIO)?
What is the market cap of Jade Biosciences (JBIO)?
